Jivana Biotechnology Inc, is Pleased to Announce the Addition of Dr.

Ajay
Maker to Its Advisory Committee

Dr. Maker brings surgical oncology experience with expertise in liver, gallbladder. colon,
pancreatic, and other cancers to Jivana Biotechnology's advisory committee.

Chicago, IL, March 16, 2017 --(PR.com)-- Jivana Biotechnology Inc is pleased to announce the addition
of Dr. Ajay Maker to its advisory committee.

"We are thrilled with this addition to our advisory committee," said Sid Hopps, president and chief
executive officer of Jivana Biotechnology." The background and experience Dr. Maker brings to Jivana is
invaluable as we move our cancer therapies into clinical development and shape our drug delivery
strategies.

Dr. Maker is a surgical oncologist with board certification in general surgery. His expertise includes
treating benign and malignant diseases of the liver, bile ducts, gallbladder, and pancreas, as well as colon
and other gastrointestinal cancers, melanoma, and sarcoma. He joined the Division of Surgical Oncology
and the Department of Microbiology and Immunology at the University of Illinois at Chicago after
completing a fellowship in surgical oncology with a focus upon hepatopancreatobiliary surgery at
Memorial Sloan-Kettering Cancer Center, and a fellowship in Tumor Immunology and Surgical
Oncology at the National Cancer Institute. Dr. Maker cares for patients as part of a multidisciplinary team
of medical oncologists, radiation oncologists, gastroenterologists, and radiologists who specialize in
treating patients with these specific cancers.

Dr. Maker graduated from Brown University with honors in fine arts and biology. Thereafter, he enrolled
in the Yale School of Medicine and was selected to enter the Basic Science Research Training Fellowship
where he was awarded the Medical Scholars Award from the American Diabetes Association and the
Association for Academic Surgery/Novartis Research Award. Upon entering the surgical residency
training program at Harvard University's Brigham and Women's Hospital, he had already chosen to
pursue a career in surgical oncology and was accepted into the post-doctoral surgical oncology fellowship
program under Dr. Steven Rosenberg in the Surgery Branch of the National Cancer Institute at the
National Institutes of Health (NCI/NIH). Thereafter, he went on to complete a surgical oncology
fellowship at the Memorial Sloan-Kettering Cancer Center.

Dr. Maker serves as a reviewer for multiple surgery and scientific journals, and is a member of multiple
academic and scientific societies, including the Society of Surgical Oncology's Gastrointestinal Oncology
Working Group, the Americas Hepatopancreatobiliary Association's research committee, and the
Association for Academic Surgery's leadership committee. He currently is Director of Surgical Oncology
for the Creticos Cancer Center and Director of Surgical Research for the University of Illinois
Metropolitan Group Hospitals General Surgery Residency Training Program. Currently, he serves as the
principal investigator on a multi-year federal research grant from the National Cancer Institute/National
Institutes of Health to study the immunobiology of GI cancers.

Page 1/3
PR.com Press Release Distribution Terms of Use
Jivana Biotechnology develops RNA interference (RNAi) therapeutics to treat a wide range of cancers
including breast, ovarian, liver, lung, thyroid and pancreatic by down modulating a specific gene product
that prevents programmed cell death. RNAi is a mechanism present in living cells that inhibits the
expression of a specific gene, affecting production of a specific protein. Jivana's RNAi-based therapeutics
help leverage this natural pathway of gene silencing.

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
Jivana Biotechnology Inc
Sidney Hopps
917.743.9401
Contact via Email
www.jivanabiotech.com

Online Version of Press Release:

You can read the online version of this press release at: http://www.pr.com/press-release/709243

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use